FY2029 Earnings Forecast for IPSC Issued By Leerink Partnrs

Century Therapeutics, Inc. (NASDAQ:IPSC) – Equities research analysts at Leerink Partnrs issued their FY2029 EPS estimates for Century Therapeutics in a research note issued to investors on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch forecasts that the company will post earnings of ($1.18) per share for the year. The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.63) per share.

Several other research firms have also recently commented on IPSC. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Century Therapeutics in a report on Wednesday, January 22nd. Guggenheim reaffirmed a “buy” rating on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Piper Sandler lowered their price target on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating on the stock in a research report on Monday, December 30th. Finally, Chardan Capital reduced their target price on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $10.00.

Century Therapeutics Trading Up 0.8 %

IPSC stock opened at $0.75 on Friday. The firm has a 50-day moving average of $0.99 and a two-hundred day moving average of $1.37. Century Therapeutics has a 12 month low of $0.68 and a 12 month high of $5.51.

Hedge Funds Weigh In On Century Therapeutics

A number of hedge funds have recently modified their holdings of IPSC. SG Americas Securities LLC acquired a new position in Century Therapeutics in the third quarter valued at about $27,000. State Street Corp raised its stake in shares of Century Therapeutics by 7.4% in the 3rd quarter. State Street Corp now owns 836,914 shares of the company’s stock valued at $1,431,000 after acquiring an additional 57,323 shares during the period. Wellington Management Group LLP acquired a new position in shares of Century Therapeutics in the 3rd quarter worth approximately $284,000. Barclays PLC lifted its holdings in shares of Century Therapeutics by 283.6% in the 3rd quarter. Barclays PLC now owns 61,945 shares of the company’s stock worth $106,000 after acquiring an additional 45,797 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Century Therapeutics by 3.5% during the 3rd quarter. Geode Capital Management LLC now owns 968,182 shares of the company’s stock worth $1,656,000 after purchasing an additional 32,614 shares during the period. 50.20% of the stock is currently owned by hedge funds and other institutional investors.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.